Estée Lauder
No proof required
Up to $5,000
Claims opening soon
A
Aurobindo, Hetero, Vivimed
A class action settlement has been reached for consumers who purchased Valsartan, Losartan, or Irbesartan medications allegedly contaminated with cancer-causing substances.
ClosedUnited States-wideClaim status: Closed on June 2, 2026Payout: $100 - $200No longer claimable
About this settlement
Allegations of contamination in Valsartan, Losartan, and Irbesartan blood pressure medications.
This settlement addresses claims that Valsartan, Losartan, and Irbesartan medications from Aurobindo, Hetero, and Vivimed were contaminated with cancer-causing substances. Different award amounts and proof requirements apply to each manufacturer.
Who qualifies
- Consumers who purchased irbesartan medications manufactured with Aurobindo irbesartan API since Jan. 1, 2016.
- Consumers who purchased valsartan medications manufactured using Hetero Process III API between May 1, 2018 and July 31, 2018.
- Consumers who purchased Vivimed losartan finished drug formulations under specific impacted National Drug Codes.
$100 - $200
Claim status: Closed on June 2, 2026
Silk and Great Value
Proof required
Up to $300,000
93 days left
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
743 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon